secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2026-08-11T21:19:43+00:00
Accession:  0001193125-26-345032
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q2 2026 net loss $4.5M; cash $62M; exaluren Phase 2b to start Q3 2026
---------------------------------------------------------------------------

- Net loss of $4.5M ($0.39/share) for Q2 2026 vs $1.9M ($5.45/share) in Q2 2025; R&D spend up to $2.8M.
- Completed $66M public offering (2.975M shares at $11.00) plus pre-funded warrants; net proceeds $58.3M.
- Cash and equivalents $62.0M as of June 30, 2026; no debt; expected to fund into mid-2028.
- Phase 2b trial of exaluren in Alport syndrome expected to start Q3 2026; topline data mid-2027.
- EU granted orphan designation for exaluren in ADPKD; Phase 2 trial planned 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/0001193125-26-345032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000119312526345032/d167833d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer